The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity

Vaccines

Volumn 3, Issue 3, 2015, Pages 703-729

  Mbongue, Jacques C ^a   Nicholas, Dequina A ^a   Torrez, Timothy W ^b   Kim, Nan Sun ^a,c   Firek, Anthony F ^d   Langridge, William H R ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CALIFORNIA BAPTIST UNIVERSITY   (United States)

^c Chonbuk National University   (South Korea)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CTB INS; Indoleamine 2, 3 dioxygenase; NF B; Tryptophan; Vaccine

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN;

ALLERGY; AMINO ACID METABOLISM; ASTROCYTE; AUTOIMMUNITY; CELL SURVIVAL; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME ACTIVITY; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; MESENCHYMAL STEM CELL; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY; UPREGULATION; VIRUS INFECTION;

EID: 85016873692     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3030703     Document Type: Review

References (154)

1. Sugimoto, H.; Oda, S.; Otsuki, T.; Hino, T.; Yoshida, T.; Shiro, Y. Crystal structure of human indoleamine 2, 3-dioxygenase: Catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc. Natl. Acad. Sci. USA 2006, 103, 2611–2616.
2. Heitger, A. Regulation of expression and function of IDO in human dendritic cells. Curr. Med. Chem. 2011, 18, 2222–2233.
3. Yuasa, H.J.; Ball, H.J.; Ho, Y.F.; Austin, C.J.; Whittington, C.M.; Belov, K.; Maghzal, G.J.; Jermiin, L.S.; Hunt, N.H. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials. Comp. Biochem. Physiol. 2009, 153, 137–144.
4. Ball, H.J.; Sanchez-Perez, A.; Weiser, S.; Austin, C.J.D.; Astelbauer, F.; Miu, J.; McQuillan, J.A.; Stocker, R.; Jermiin, L.S.; Hunt, N.H. Characterization of an indoleamine 2, 3-dioxygenase-like protein found in humans and mice. Gene 2007, 396, 203–213.
5. Zhang, Y.; Kang, S.A.; Mukherjee, T.; Bale, S.; Crane, B.R.; Begley, T.P.; Ealick, S.E. Crystal structure and mechanism of tryptophan 2, 3-dioxygenase, a heme enzyme involved in tryptophan catabolism and in quinolinate biosynthesis. Biochemistry 2007, 46, 145–155.
6. Panozzo, C.; Nawara, M.; Suski, C.; Kucharczyka, R.; Skoneczny, M.; Bécam, A.-M.; Rytka, J.; Herbert, C.J. Aerobic and anaerobic NAD+ metabolism in Saccharomyces cerevisiae. FEBS Lett. 2002, 517, 97–102.
7. Metz, R.; Duhadaway, J.B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A.J.; Prendergast, G.C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007, 67, 7082–7087.
8. Lob, S.; Königsrainer, A.; Zieker, D.; Brücher, B.L.; Rammensee, H.G.; Opelz, G.; Terness, P. IDO1 and IDO2 are expressed in human tumors: Levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 2009, 58, 153–157.
9. Prendergast, G.C.; Metz, R.; Muller, A.J.; Merlo, L.M.; Mandik-Nayak, L. IDO2 in immunomodulation and autoimmune disease. Front. Immunol. 2014, doi:10.3389/fimmu.2014.00585.
10. Najfeld, V.; Menninger, J.; Muhleman, D.; Comings, D.E.; Gupta, S.L. Localization of indoleamine 2, 3-dioxygenase gene (INDO) to chromosome 8p12 ≥ p11 by fluorescent in situ hybridization. Cytogenet. Cell Genet. 1993, 64, 231–232.
11. Belladonna, M.L.; Puccetti, P.; Orabona, C.; Fallarino, F.; Vacca, C.; Volpi, C.; Gizzi, S.; Pallotta, M.T.; Fioretti, M.C.; Grohmann, U. Immunosuppression via tryptophan catabolism: The role of kynurenine pathway enzymes. Transplantation 2007, 84, S17–S20.
12. Mellor, A.L.; Chandler, P.; Lee, G.K.; Johnson, T.; Keskin, D.B.; Lee, J.; Munn, D.H. Indoleamine 2, 3-dioxygenase, immunosuppression and pregnancy. J. Reprod. Immunol. 2002, 57, 143–150.
13. Mellor, A. Indoleamine 2, 3-dioxygenase and regulation of T cell immunity. Biochem. Biophys. Res. Commun. 2005, 338, 20–24.
14. Munn, D.H.; Sharma, M.D.; Baban, B.; Harding, H.P.; Zhang, Y.; Ron, D.; Mellor, A.L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 2005, 22, 633–642.
15. Grohmann, U.; Fallarino, F.; Puccetti, P. Tolerance, DCs and tryptophan: Much ado about IDO. Trends Immunol.2003, 24, 242–248.
16. Munn, D.H.; Zhou, M.; Attwood, J.T.; Bondarev, I.; Conway, S.J.; Marshall, B.; Brown, C.; Mellor, A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281, 1191–1193.
17. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; Marshak, D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, 143–147.
18. Bianco, P.; Riminucci, M.; Gronthos, S.; Robey, P.G. Bone marrow stromal stem cells: Nature, biology, and potential applications. Stem Cells 2001, 19, 180–192.
19. Su, J.; Chen, X.; Huang, Y.; Li, W.; Li, J.; Cao, K.; Cao, G.; Zhang, L.; Li, F.; Roberts, A.I., et al.Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ. 2014, 21, 388–396.
20. Shi, Y.F.; Su, J.J.; Roberts, A.I.; Shou, P.; Rabson, A.B.; Ren, G.W. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 2012, 33, 136–143.
21. Meisel, R.; Laryea, M.; Göbel, U.; Däubener, W.; Dilloo, D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103, 4619–4621.
22. Ren, G.W.; Su, J.; Zhang, L.; Zhao, X.; Ling, W.; L’huillie, A.; Zhang, J.; Lu, Y.; Roberts, A.I.; Ji, W., et al.Species variation in the mechanisms of mesenchymal stem cell-mediated Immunosuppression. Stem Cells 2009, 27, 1954–1962.
23. Bernardo, M.E.; Fibbe, W.E. Mesenchymal stromal cells: Sensors and switchers of inflammation. Cell Stem Cell 2013, 13, 392–402.
24. Dong, Y.; Benveniste, E.N. Immune function of astrocytes. Glia 2001, 36, 180–190.
25. Adam, R.; Rüssing, D.; Adams, O.; Ailyati, A.; Sik Kim, K.; Schroten, H.; Däubener, W. Role of human brain microvascular endothelial cells during central nervous system infection. Significance of indoleamine 2, 3-dioxygenase in antimicrobial defence and immunoregulation. Thromb. Haemost. 2005, 94, 341–346.
26. Kwidzinski, E.; Bechmann, I. IDO expression in the brain: A double-edged sword. J. Mol. Med. (Berl) 2007, 85, 1351–1359.
27. Suh, H.S.; Zhao, M.L.; Rivieccio, M.; Choi, S.; Connolly, E.; Zhao, Y.; Takikawa, O.; Brosnan, C.F.; Lee, S.C. Astrocyte indoleamine 2, 3-dioxygenase is induced by the TLR3 ligand poly(I:C): Mechanism of induction and role in antiviral response. J. Virol. 2007, 81, 9838–9850.
28. Carpentier, P.A.; Begolka, W.S.; Olson, J.K.; Elhofy, A.; Karpus, W.J.; Miller, S.D. Differential activation of astrocytes by innate and adaptive immune stimuli. Glia 2005, 49, 360–374.
29. Farina, C.; Krumbholz, M.; Giese, T.; Hartmann, G.; Aloisi, F.; Meinl, E. Preferential expression and function of Toll-like receptor 3 in human astrocytes. J. Neuroimmunol. 2005, 159, 12–19.
30. Chiarugi, A.; Meli, E.; Moroni, F. Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J. Neurochem. 2001, 77, 1310–1318.
31. Okuda, S.; Nishiyama, N.; Saito, H.; Katsuki, H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc. Natl. Acad. Sci. USA 1996, 93, 12553–12558.
32. Heine, W.; Radke, M.; Wutzke, K.D. The significance of tryptophan in human nutrition. Amino Acids 1995, 9, 91–205.
33. Sasaki, E.; Ohta, Y.; Shinohara, R.; Ishiguro, I. Contribution of serum albumin to the transport of orally administered L-tryptophan into liver of rats with L-tryptophan depletion. Amino Acids 1999, 16, 29–39.
34. Mbongue, J.C.; Nicholas, D.A.; Zhang, K.; Kim, N.S.; Hamilton, B.N.; Larios, M.; Zhang, G.; Umezawa, K.; Firek, A.F.; Langridge, W.H. Induction of indoleamine 2, 3-dioxygenase in human dendritic cells by a cholera toxin B subunit-proinsulin vaccine. PLoS ONE2015, 10, e0118562.
35. Tas, S.W.; Vervoordeldonk, M.J.; Hajji, N.; Schuitemake, J.H.N.; van der Sluijs, K.F.; May, M.J.; Ghosh, S.; Kapsenberg, M.L.; Tak, P.P.; de Jong, E.C. Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2, 3-dioxygenase (IDO) induction and immune regulation. Blood 2007, 110, 1540–1549.
36. Du, M.X.; Sotero-Esteva, W.D.; Taylor, M.W. Analysis of transcription factors regulating induction of indoleamine 2, 3-dioxygenase by IFN-gamma. J. Interferon Cytokine Res. 2000, 20, 133–142.
37. Courtney, J.M.; Falkenhagen, D.; Ivanovich, P.; Schuett, W. Adsorption technologies and blood purification procedures: Honoring horst klinkmann.Artif. Organs 2002, 26, 84–208.
38. Chon, S.Y.; Hassanain, H.H.; Pine, R.; Gupta, S.L. Involvement of two regulatory elements in interferon-gamma-regulated expression of human indoleamine 2, 3-dioxygenase gene. J. Interferon Cytokine Res. 1995, 15, 517–526.
39. Robinson, C.M.; Hale, P.T.; Carlin, J.M. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J. Interferon Cytokine Res. 2005, 25, 20–30.
40. Konan, K.V.; Taylor, M.W. Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2, 3-dioxygenase gene. J. Biol. Chem. 1996, 271, 19140–19145.
41. Bonizzi, G.; Bebien, M.; Otero, D.C.; Johnson-Vroom, K.E.; Cao, Y.; Vu, D.; Jegga, A.G.; Aronow, B.J.; Ghosh, G.; Rickert, R.C., et al. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J. 2004, 23, 4202–4210.
42. Puccetti, P.; Grohmann, U. IDO and regulatory T cells: A role for reverse signalling and non-canonical NF-kappaB activation. Nat. Rev. Immunol. 2007, 7, 817–823.
43. Manches, O.; Fernandez, M.V.; Plumas, J.; Chaperot, L.; Bhardwaj, N. Activation of the noncanonical NF-kappaB pathway by HIV controls a dendritic cell immunoregulatory phenotype. Proc. Natl. Acad. Sci. USA 2012, 109, 14122–14127.
44. Robinson, C.M.; Hale, P.T.; Carlin, J.M. NF-kappa B activation contributes to indoleamine dioxygenase transcriptional synergy induced by IFN-gamma and tumor necrosis factor-alpha. Cytokine 2006, 35, 53–61.
45. Li, W.; Katz, B.; Spinola, S.M. Haemophilus ducreyi lipooligosaccharides induce expression of the immunosuppressive enzyme indoleamine 2, 3-dioxygenase via type I interferons and tumor necrosis factor alpha in human dendritic cells. Infect. Immun. 2011, 79, 3338–3347.
46. Fujigaki, S.; Saito, K.; Sekikawa, K.; Tone, S.; Takikawa, O.; Fujii, H.; Wada, H.; Noma, A.; Seishima, M. Lipopolysaccharide induction of indoleamine 2, 3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur. J. Immunol. 2001, 31, 2313–2318.
47. Horvath, C.M. The Jak-STAT pathway stimulated by interferon gamma. Sci. STKE 2004, doi:10.1126/stke.2602004tr8.
48. Jurgens, B.; Hainz, U.; Fuchs, D.; Felzmann, T.; Heitger, A. Interferon-gamma-triggered indoleamine 2, 3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 2009, 114, 3235–3243.
49. Pallotta, M.T.; Orabona, C.; Volpi, C.; Vacca, C.; Belladonna, M.L.; Bianchi, R.; Servillo, G.; Brunacci, C.; Calvitti, M.; Bicciato, S., et al. Indoleamine 2, 3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 2011, 12, 870–878.
50. Shi, Y.; Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113, 685–700.
51. Nguyen, N.T.; Kimura, A.; Nakahama, T.; Chinen, I.; Masuda, K.; Nohara, K.; Fujii-Kuriyama, Y.; Kishimoto, T. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. USA 2010, 107, 19961–19966.
52. Vogel, C.F.; Wu, D.; Goth, S.R.; Baek, J.; Lollies, A.; Domhardt, R.; Grindel, A.; Pessah, I.N. Aryl hydrocarbon receptor signaling regulates NF-kappaB RelB activation during dendritic-cell differentiation. Immunol. Cell Biol. 2013, 91, 568–575.
53. Mezrich, J.D.; Fechner, J.H.; Zhang, X.; Johnson, B.P.; Burlingham, W.J.; Bradfield, C.A. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010, 185, 3190–3198.
54. Iwata, H.; Mizuno, S.; Ishikawa, E.; Tanemura, A.; Murata, Y.; Kuriyama, N.; Azumi, Y.; Kishiwada, M.; Usui, M.; Sakurai, H., et al. Negative prognostic impact of renal replacement therapy in adult living-donor liver transplant recipients: Preoperative recipient condition and donor factors. Transplant. Proc. 2014, 46, 716–720.
55. Fallarino, F.; Grohmann, U.; You, S.; McGrath, B.C.; Cavener, D.R.; Vacca, C.; Orabona, C.; Bianchi, R.; Belladonna, M.L.; Volpi, C.; et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006, 176, 6752–6761.
56. Zaher, S.S.; Germain, C.; Fu, H.; Larkin, D.F.; George, A.J. 3-Hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival. Investig. Ophthalmol. Vis. Sci. 2011, 52, 2640–2648.
57. Pop, S.M.; Wong, C.P.; He, Q.; Wang, Y.; Wallet, M.A.; Goudy, K.S.; Tisch, R. The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes 2007, 56, 1395–1402.
58. Harden, J.L.; Egilmez, N.K. Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity. Immunol. Investig. 2012, 41, 738–764.
59. Mbongue, J.; Nicholas, D.; Firek, A.; Langridge, W. The role of dendritic cells in tissue-specific autoimmunity. J. Immunol. Res. 2014, doi:10.1155/2014/857143.
60. Chaudhary, K.; Shinde, R.; Liu, H.; Gnana-Prakasam, J.P.; Veeranan-Karmegam, R.; Huang, L.; Ravishankar, B.; Bradley, J.; Kvirkvelia, N.; McMenamin, M., et al. Amino acid metabolism inhibits antibody-driven kidney injury by inducing autophagy. J. Immunol. 2015, 194, 5713–5724.
61. Belladonna, M.L.; Orabona, C.; Grohmann, U.; Puccetti, P. TGF-beta and kynurenines as the key to infectious tolerance. Trends Mol. Med. 2009, 15, 41–49.
62. Fallarino, F.; Grohmann, U.; Vacca, C.; Bianchi, R.; Orabona, C.; Spreca, A.; Fioretti, M.C.; Puccetti, P. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002, 9, 1069–1077.
63. Terness, P.; Bauer, T.M.; Röse, L.; Dufter, C.; Watzlik, A.; Simon, H.; Opelz, G. Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites. J. Exp. Med. 2002, 196, 447–457.
64. Frumento, G.; Rotondo, R.; Tonetti, M.; Damonte, G.; Benatti, U.; Ferrara, G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J. Exp. Med. 2002, 196, 459–468.
65. Pallotta, M.T.; Orabona, C.; Bianchi, R.; Vacca, C.; Fallarino, F.; Belladonna, M.L.; Volpi, C.; Mondanelli, G.; Gargaro, M.; Allegrucci, M., et al. Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes. J. Cell. Mol. Med. 2014, 18, 2082–2091.
66. Belladonna, M.L.; Volpi, C.; Bianchi, R.; Vacca, C.; Orabona, C.; Pallotta, M.T.; Boon, L.; Gizzi, S.; Fioretti, M.C.; Grohmann, U., et al. Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 2008, 181, 5194–5198.
67. Vollmer, J.; Weeratna, R.; Payette, P.; Jurk, M.; Schetter, C.; Laucht, M.; Wader, T.; Tluk, S.; Liu, M.; Davis, H.L., et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 2004, 34, 251–262.
68. Mellor, A.L.; Baban, B.; Chandler, P.R.; Manlapat, A.; Kahler, D.J.; Munn, D.H. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2, 3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. 2005, 175, 5601–5605.
69. Johnson, B.A., 3rd; Kahler, D.J.; Baban, B.; Chandler, P.R.; Kang, B.; Shimoda, M.; Koni, P.A.; Pihkala, J.; Vilagos, B.; Busslinger, M., et al. B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2, 3-dioxygenase. Proc. Natl. Acad. Sci. USA 2010, 107, 10644–10648.
70. Opitz, C.A.; Litzenburger, U.M.; Sahm, F.; Ott, M.; Tritschler, I.; Trump, S.; Schumacher, T.; Jestaedt, L.; Schrenk, D.; Weller, M., et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478, 197–203.
71. Fallarino, F.; Volpi, C.; Zelante, T.; Vacca, C.; Calvitti, M.; Fioretti, M.C.; Puccetti, P.; Romani, L.; Grohmann, U. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J. Immunol. 2009, 183, 6303–6312.
72. Lind, E.F.; Ahonen, C.L.; Wasiuk, A.; Kosaka, Y.; Becher, B.; Bennett, K.A.; Noelle, R.J. Dendritic cells require the NF-kappaB2 pathway for cross-presentation of soluble antigens. J. Immunol. 2008, 181, 354–363.
73. An, H.; Hou, J.; Zhou, J.; Zhao, W.; Xu, H.; Zheng, Y.; Yu, Y.; Liu, S.; Cao, X. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat. Immunol. 2008, 9, 542–550.
74. Fukui, T.; Tabata, M.; Taguri, M.; Manabe, S.; Morita, S.; Takanashi, S. Extensive reconstruction of the left anterior descending coronary artery with an internal thoracic artery graft. Ann. Thorac. Surg. 2011, 91, 445–451.
75. Sucher, R.; Fischler, K.; Oberhuber, R.; Kronberger, I.; Margreiter, C.; Ollinger, R.; Schneeberger, S.; Fuchs, D.; Werner, E.R.; Watschinger, K., et al. IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival. J. Immunol. 2012, 188, 37–46.
76. Bock, F.; Rössner, S.; Onderka, J.; Lechmann, M.; Pallotta, M.T.; Fallarino, F.; Boon, L.; Nicolette, C.; DeBenedette, M.A.; Tcherepanova, I.Y., et al. Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. J. Immunol. 2013, 191, 1965–1975.
77. Brandacher, G.; Cakar, F.; Winkler, C.; Schneeberger, S.; Obrist, P.; Bösmüller, C.; Werner-Felmayer, G.; Werner, E.R.; Bonatti, H.; Margreiter, R., et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int. 2007, 71, 60–67.
78. Liu, H.Z.; Liu, L.; Liu, K.; Bizargity, P.; Hancock, W.W.; Visner, G.A. Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2, 3-dioxygenase-dependent immune suppression. J. Immunol. 2009, 183, 1022–1031.
79. Liu, W.L.; Lin, Y.H.; Xiao, H.; Xing, S.; Chen, H.; Chi, P.D.; Zhang, G. Epstein-Barr virus infection induces indoleamine 2, 3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-kappaB pathways: Impairment in T cell functions. J. Virol. 2014, 88, 6660–6671.
80. Grant, R.S.; Naif, H.; Thuruthyil, S.J.; Nasr, N.; Littlejohn, T.; Takikawa, O.; Kapoor, V. Induction of indolamine 2, 3-dioxygenase in primary human macrophages by human immunodeficiency virus type 1 is strain dependent. J. Virol. 2000, 74, 4110–4115.
81. Boasso, A.; Herbeuval, J.P.; Hardy, A.W.; Anderson, S.A.; Dolan, M.J.; Fuchs, D.; Shearer, G.M. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2, 3-dioxygenase in plasmacytoid dendritic cells. Blood 2007, 109, 3351–3359.
82. Douek, D.C.; Roederer, M.; Koup, R.A. Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med. 2009, 60, 471–484.
83. Cunningham, A.L.; Donaghy, H.; Harman, A.N.; Kim, M.; Turville, S.G. Manipulation of dendritic cell function by viruses. Curr. Opin. Microbiol. 2010, 13, 524–529.
84. Fauci, A.S.; Pantaleo, G.; Stanley, S.; Weissman, D. Immunopathogenic mechanisms of HIV infection. Ann. Intern. Med. 1996, 124, 654–663.
85. Fuchs, D.; Forsman, A.; Hagberg, L.; Larsson, M.; Norkrans, G.; Reibnegger, G.; Werner, E.R.; Wachter, H. Immune activation and decreased tryptophan in patients with HIV-1 infection. J. Interferon Res. 1990, 10, 599–603.
86. Linde, A. Diagnosis of Epstein-Barr virus-related diseases. Scand. J. Infect. Dis. Suppl. 1996, 100, 83–88.
87. Maeda, E.; Akahane, M.; Kiryu, S.; Kato, N.; Yoshikawa, T.; Hayashi, N.; Aoki, S.; Minami, M.; Uozaki, H.; Fukayama, M., et al.Spectrum of Epstein-Barr virus-related diseases: A pictorial review. Jpn. J .Radiol. 2009, 27, 4–19.
88. Tugizov, S.; Herrera, R.; Veluppillai, P.; Greenspan, J.; Greenspan, D.; Palefsky, J.M. Epstein-Barr virus (EBV)-infected monocytes facilitate dissemination of EBV within the oral mucosal epithelium. J. Virol. 2007, 81, 5484–5496.
89. Walling, D.M.; Ray, A.J.; Nichols, J.E.; Flaitz, C.M.; Nichols, C.M. Epstein-Barr virus infection of Langerhans cell precursors as a mechanism of oral epithelial entry, persistence, and reactivation. J. Virol. 2007, 81, 7249–7268.
90. Savard, M.; Bélanger, C.; Tremblay, M.J.; Dumais, N.; Flamand, L.; Borgeat, P.; Gosselin, J. EBV suppresses prostaglandin E2 biosynthesis in human monocytes. J. Immunol. 2000, 164, 6467–6473.
91. Savard, M.; Bélanger, C.; Tardif, M.; Gourde, P.; Flamand, L.; Gosselin, J.Infection of primary human monocytes by Epstein-Barr virus. J. Virol. 2000, 74, 2612–2619.
92. Muller, A.J.; Prendergast, G.C. Marrying immunotherapy with chemotherapy: Why say IDO? Cancer Res.2005, 65, 8065–8068.
93. Platten, M.; von Knebel Doeberitz, N.; Oezen, I.; Wick, W.; Ochs, K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front. Immunol. 2014, doi:10.3389/fimmu.2014.00673.
94. Platten, M.; Wick, W.; van den Eynde, B.J. Tryptophan catabolism in cancer: Beyond IDO and tryptophan depletion. Cancer Res. 2012, 72, 5435–5440.
95. Lob, S.; Konigsrainer, A.; Schafer, R.; Rammensee, H.G.; Opelz, G.; Terness, P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008, 111, 2152–2154.
96. Thaker, A.I.; Rao, M.S.; Bishnupuri, K.S.; Kerr, T.A.; Foster, L.; Marinshaw, J.M.; Newberry, R.D.; Stenson, W.F.; Ciorba, M.A. IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology 2013, 145, 416–425.
97. Ino, K.; Yamamoto, E.; Shibata, K.; Kajiyama, H.; Yoshida, N.; Terauchi, M.; Nawa, A.; Nagasaka, T.; Takikawa, O.; Kikkawa, F. Inverse correlation between tumoral indoleamine 2, 3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival. Clin. Cancer Res. 2008, 14, 2310–2317.
98. Jacobs, J.F.; Idema, A.J.; Bol, K.F.; Grotenhuis, J.A.; de Vries, I.J.; Wesseling, P.; Adema, G.J. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J. Neuroimmunol. 2010, 225, 195–199.
99. Wainwright, D.A.; Balyasnikova, I.V.; Chang, A.L.; Ahmed, A.U.; Moon, K.S.; Auffinger, B.; Tobias, A.L.; Han, Y.; Lesniak, M.S. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 2012, 18, 6110–6121.
100. Li, M.; Bolduc, A.R.; Hoda, M.N.; Gamble, D.N.; Dolisca, S.-B.; Bolduc, A.K.; oang, K.; Ashley, C.; McCall, D.; Rojiani, A.M., et al.The indoleamine 2, 3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J. Immunother. Cancer 2014, doi:10.1186/2051-1426-2-21.
101. Chen, J.Y.; Li, C.-F.; Kuo, C.-C.; Tsai, K.K.; Hou, M.-F.; Hung, W.-C. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2, 3-dioxygenase promotes breast cancer progression. Breast Cancer Res. 2014, doi:10.1186/s13058-014-0410-1.
102. Soliman, H.; Rawal, B.; Fulp, J.; Lee, J.H.; Lopez, A.; Bui, M.M.; Khalil, F.; Antonia, S.; Yfantis, H.G.; Lee, D.H.; Dorsey, T.H.; Ambs, S. Analysis of indoleamine 2–3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol. Immunother. 2013, 62, 829–837.
103. Boyland, E.; Williams, D.C. Metabolism of tryptophan. 2. Metabolism of tryptophan in patients suffering from cancer of the bladder. Biochem. J. 1956, 64, 578–582.
104. Friberg, M.; Jennings, R.; Alsarraj, M.; Dessureault, S.; Cantor, A.; Extermann, M.; Mellor, A.L.; Munn, D.H.; Antonia, S.J. Indoleamine 2, 3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 2002, 101, 151–155.
105. Uyttenhove, C.; Pilotte, L.; Théate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9, 1269–1274.
106. Muller, A.J.; DuHadaway, J.B.; Donover, P.S.; Sutanto-Ward, E.; Prendergast, G.C. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11, 312–319.
107. Palucka, A.K.; Ueno, H.; Fay, J.; Banchereau, J. Dendritic cells: A critical player in cancer therapy? J. Immunother. 2008, 31, 793–805.
108. Palucka, K.; Banchereau, J.; Mellman, I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33, 464–478.
109. Palucka, K.; Ueno, H.; Banchereau, J. Recent developments in cancer vaccines. J. Immunol. 2011, 186, 1325–1331.
110. Kishimoto, H.; Sprent, J. A defect in central tolerance in NOD mice. Nat. Immunol. 2001, 2, 1025–1031.
111. Fallarino, F.; Bianchi, R.; Orabona, C.; Vacca, C.; Belladonna, M.L.; Fioretti, M.C.; Serreze, D.V.; Grohmann, U.; Puccetti, P. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J. Exp. Med.2004, 200, 1051–1062.
112. Martino, G.; Hartung, H.P. Immunopathogenesis of multiple sclerosis: The role of T cells. Curr. Opin. Neurol. 1999, 12, 309–321.
113. Lanz, T.V.; Opitz, C.A.; Ho, P.P.; Agrawal, A.; Lutz, C.; Weller, M.; Mellor, A.L.; Steinman, L.; Wick, W.; Platten, M. Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells Dev. 2010, 19, 657–668.
114. Sakurai, K.; Zou, J.P.; Tschetter, J.R.; Ward, J.M.; Shearer, G.M. Effect of indoleamine 2, 3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002, 129, 186–196.
115. Kwidzinski, E.; Bunse, J.; Kovac, A.D.; Ullrich, O.; Zipp, F.; Nitsch, R.; Bechmann, I. IDO (indolamine 2, 3-dioxygenase) expression and function in the CNS. Adv. Exp. Med. Biol. 2003, 527, 113–118.
116. Lemos, H.; Huang, L.; Chandler, P.R.; Mohamed, E.; Souza, G.R.; Li, L.; Pacholczyk, G.; Barber, G.N.; Hayakawa, Y.; Munn, D.H.; Mellor, A.L. Activation of the STING adaptor attenuates experimental autoimmune encephalitis. J. Immunol. 2014, 192, 5571–5578.
117. Cernea, S.; Dobreanu, M.; Raz, I. Prevention of type 1 diabetes: Today and tomorrow. Diabetes Metab. Res. Rev. 2010, 26, 602–605.
118. Gupta, S.K. Vaccines for type 1 diabetes in the late stage of clinical development. Indian J. Pharmacol. 2011, doi:10.4103/0253-7613.83130.
119. Harrison, L.C. The prospect of vaccination to prevent type 1 diabetes. Hum. Vaccin. 2005, 1, 143–150.
120. Odumosu, O.; Nicholas, D.; Yano, H.; Langridge, W. AB toxins: A paradigm switch from deadly to desirable. Toxins (Basel) 2010, 2, 1612–1645.
121. Denes, B.; Krausova, V.; Fodor, N.; Timiryasova, T.; Henderson, D.; Hough, J.; Yu, J.; Fodor, I.; Langridge, W.H. Protection of NOD mice from type 1 diabetes after oral inoculation with vaccinia viruses expressing adjuvanted islet autoantigens. J. Immunother. 2005, 28, 438–448.
122. Bergerot, I.; Ploix, C.; Petersen, J.; Moulin, V.; Rask, C.; Fabien, N.; Lindblad, M.; Mayer, A.; Czerkinsky, C.; Holmgren, J.; Thivolet, C. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl. Acad. Sci. USA 1997, 94, 4610–4614.
123. George-Chandy, A.; Eriksson, K.; Lebens, M.; Nordström, I.; Schön, E.; Holmgren, J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect. Immun. 2001, 69, 5716–5725.
124. Arakawa, T.; Chong, D.K.; Langridge, W.H. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. 1998, 16, 292–297.
125. Odumosu, O.; Nicholas, D.; Payne, K.; Langridge, W. Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function. Vaccine 2011, 29, 8451–8458.
126. D’Ambrosio, A.; Colucci, M.; Pugliese, O.; Quintieri, F.; Boirivant, M. Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation. J. Leukoc. Biol. 2008, 84, 661–668.
127. Kaneko, S.; Suzuki, N.; Yamashita, N.; Nagafuchi, H.; Nakajima, T.; Wakisaka, S.; Yamamoto, S.; Sakane, T. Characterization of T cells specific for an epitope of human 60-kD heat shock protein (HSP) in patients with Behcet’s disease (BD) in Japan. Clin. Exp. Immunol. 1997, 108, 204–212.
128. Pickering, M.C.; Haskard, D.O. Behcet’s syndrome. J. R. Coll. Physicians Lond. 2000, 34, 169–177.
129. Phipps, P.A.; Stanford, M.R.; Sun, J.B.; Xiao, B.G.; Holmgren, J.; Shinnick, T.; Hasan, A.; Mizushima, Y.; Lehner, T. Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur. J. Immunol. 2003, 33, 224–232.
130. Stanford, M.; Whittall, T.; Bergmeier, L.A.; Lindblad, M.; Lundin, S.; Shinnick, T.; Mizushima, Y.; Holmgren, J.; Lehner, T. Oral tolerization with peptide 336–351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet’s disease. Clin. Exp. Immunol. 2004, 137, 201–208.
131. Clements, C.S.; Reid, H.H.; Beddoe, T.; Tynan, F.E.; Perugini, M.A.; Johns, T.G.; Bernard, C.C.; Rossjohn, J. The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2003, 100, 11059–11064.
132. Anderson, G.; Rodriguez, M. Multiple sclerosis, seizures, and antiepileptics: Role of IL-18, IDO, and melatonin. Eur. J. Neurol. 2011, 18, 680–685.
133. Sun, J.B.; Czerkinsky, C.; Holmgren, J. B Lymphocytes treated in vitro with antigen coupled to cholera toxin B subunit induce antigen-specific Foxp3(+) regulatory T cells and protect against experimental autoimmune encephalomyelitis. J. Immunol. 2012, 188, 1686–1697.
134. Tisch, R.; McDevitt, H. Insulin-dependent diabetes mellitus. Cell 1996, 85, 291–297.
135. Eisenbarth, G.S. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 1986, 314, 1360–1368.
136. Melendez-Ramirez, L.Y.; Richards, R.J.; Cefalu, W.T. Complications of type 1 diabetes. Endocrinol. Metab. Clin. N. Am. 2010, 39, 625–640.
137. Forbes, J.M.; Cooper, M.E. Mechanisms of diabetic complications. Physiol. Rev. 2013, 93, 137–188.
138. Ploix, C.; Bergerot, I.; Durand, A.; Czerkinsky, C.; Holmgren, J.; Thivolet, C. Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes 1999, 48, 2150–2156.
139. Denes, B.; Yu, J.; Fodor, N.; Takátsy, Z.; Fodor, I.; Langridge, W.H. Suppression of hyperglycemia in NOD mice after inoculation with recombinant vaccinia viruses. Mol. Biotechnol. 2006, 34, 317–327.
140. Meng, Q.; Wang, W.; Shi, X.; Jin, Y.; Zhang, Y. Protection against autoimmune diabetes by silkworm-produced GFP-tagged CTB-insulin fusion protein. Clin. Dev. Immunol. 2011, doi:10.1155/2011/831704
141. Cooper, G.S.; Stroehla, B.C. The epidemiology of autoimmune diseases. Autoimmun. Rev. 2003, 2, 119–125.
142. Jacobson, D.L.; Gange, S.J.; Rose, N.R.; Graham, N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 1997, 84, 223–243.
143. Walsh, S.J.; Rau, L.M. Autoimmune diseases: A leading cause of death among young and middle-aged women in the United States. Am. J. Public Health 2000, 90, 1463–1466.
144. Ganguly, D.; Haak, S.; Sisirak, V.; Reizis, B. The role of dendritic cells in autoimmunity. Nat. Rev. Immunol. 2013, 13, 566–577.
145. Lee, C.N.; Lew, A.M.; Wu, L. The potential role of dendritic cells in the therapy of Type 1 diabetes. Immunotherapy 2013, 5, 591–606.
146. Lewis, K.L.; Reizis, B. Dendritic cells: Arbiters of immunity and immunological tolerance. Cold Spring Harb. Perspect. Biol. 2012, 4, a007401.
147. Garbi, N.; Kreutzberg, T. Dendritic cells enhance the antigen sensitivity of T cells. Front. Immunol. 2012, doi:10.3389/fimmu.2012.00389.
148. Itano, A.A.; McSorley, S.J.; Reinhardt, R.L.; Ehst, B.D.; Ingulli, E.; Rudensky, A.Y.; Jenkins, M.K. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 2003, 19, 47–57.
149. Wallet, M.A.; Flores, R.R.; Wanga, Y.; Yi, Z.; Kroger, C.J.; Mathews, C.E.; Earp, H.S.; Matsushima, G.; Wang, B.; Tisch, R. MerTK regulates thymic selection of autoreactive T cells. Proc. Natl. Acad. Sci. USA 2009, 106, 4810–4815.
150. Yan, Y.; Zhang, G.X.; Gran, B.; Fallarino, F.; Yu, S.; Li, H.; Cullimore, M.L.; Rostami, A.; Xu, H. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. 2010, 185, 5953–5961.
151. Aspord, C.; Thivolet, C. Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin. Exp. Immunol. 2002, 130, 204–211.
152. Petrovsky, N.; Silva, D.; Schatz, D.A. Vaccine therapies for the prevention of type 1 diabetes mellitus. Paediatr. Drugs 2003, 5, 575–582.
153. Odumosu, O.; Payne, K.; Baez, I.; Jutzy, J.; Wall, N.; Langridge, W. Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit. Immunobiology 2011, 216, 447–456.
154. Kuroki, K.; Hirose, K.; Oabe, Y.; Fukunaga, Y.; Takahashi, A.; Shiroishi, M.; Kajikawa, M.; Tabata, S.; Nakamura, S.; Takai, T. The long-term immunosuppressive effects of disulfide-linked HLA-G dimer in mice with collagen-induced arthritis. Hum. Immunol. 2013, 74, 433–438.